Medicilon Logo
search icon search icon language icon contact icon menu icon
Medicilon Logo
search icon close search icon language icon contact icon menu icon
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button
Customer Center
Customer Center

Medicilon Assists Longsee Biomedical's live bacteria preparation LF01 capsules approved for clinical use

Page View:

On November 20, LF01, an innovative anti-tumor drug independently developed by Longsee Biomedical Co. Ltd. (Longsee Biomedical), received the NMPA drug clinical trial approval notice.

Shanghai Medicilon Inc. (Medicilon), as a partner of Longsee Biomedical, provided non-clinical safety evaluation and filing application services for the research and development of LF01, and made every effort to promote the high-quality and efficient completion of the project.

Medicilon's preclinical research laboratory has passed the International Laboratory Animal Assessment and Accreditation (AAALAC) and meets the GLP standards of the US FDA and China's NMPA. In addition, the preclinical safety evaluation complies with the Organization for Economic Cooperation and Development (OECD) GLP specifications.  After years of accumulated experience and multiple verifications, Medicilon's preclinical research segment has established advanced small molecule and macromolecule bioanalysis platforms, immune analysis workstations, sample management platforms, as well as preclinical in vivo and in vitro pharmacokinetics research platforms.  Medicilon also has a complete animal model library to provide one-stop preclinical research services.

Learn more about Medicilon's safety evaluation services.

About Longsee Biomedical

 Longsee Biomedical Co. Ltd. was established in 2015 and is deeply involved in research and industrialization in the field of human microecology.  With new food and drug raw materials as its core products, Longsee Biomedical has opened up the five major links of "sourcing, storage, selection, production and use" to build a full industrial chain of biomanufacturing.

About Medicilon 

Since the founding of our company in 2004, Medicilon (Stock Code: 688202.SH) has grown into one of the professional drug discovery contract research organizations (CRO) in China.  Over the years, Medicilon keeps improving their services in biotechnology and pharmaceutical research.  Their services now span across medicinal chemistry, process chemistry, in vitro and in vivo DMPK, preclinical development and bioanalytical support.  By the end of June 2023, Medicilon has provided new drug R&D services to more than 2,000 clients around the world, and participated in the R&D of 385 new drug projects that have been approved for clinical trials.  Medicilon is proud to contribute to human health in the globe.

Relevant News